The "No Handouts for Drug Advertisements Act" would prohibit pharmaceutical companies from deducting advertising expenses when they promote prescription drugs directly to the general public. The bill targets direct-to-consumer advertising through television, radio, social media, billboards, direct mail, and other mass-market channels, while carving out an exception for ads in medical journals and professional publications. This change to tax law would apply to prescription drug manufacturers and companies that own compounding facilities. The legislation would take effect immediately upon passage for all advertising expenses paid or incurred after the bill's enactment. By eliminating this tax deduction, the bill aims to reduce the financial incentives for pharmaceutical companies to spend heavily on direct marketing to consumers.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.